China Heal Plus

HEALTHCARE UPDATE

FDA Expands Anktiva Approval for Bladder Cancer

By China Heal Plus · Updated

The FDA expanded Anktiva’s bladder cancer indication on October 14. Separately, China’s medical insurance authority outlined priorities for medical imaging records at an October 13 meeting.

A Broader US Bladder Cancer Indication

The US authorization for Anktiva (nogapendekin alfa inbakicept-pmln), used with BCG, now includes adults with BCG-unresponsive, non-muscle invasive bladder cancer with high-grade papillary-only tumors. Previously, the indication covered carcinoma in situ, with or without papillary tumors. The FDA also warns that delaying bladder-removal surgery can allow the cancer to spread.

For someone seeking a second opinion, pathology findings and the history of BCG treatment are important records to include. A specialist needs to assess how any new authorization relates to the individual case. US approval does not establish access or insurance coverage elsewhere.

Sources: [1]

China Sets Priorities for Medical Imaging Records

In an October 14 report on its previous day’s meeting, China’s National Healthcare Security Administration called for faster collection and uploading of medical imaging cloud indexes, alongside pilots for personal medical insurance data services. These are infrastructure priorities; the report does not announce a nationwide portal that overseas patients can already use.

When arranging a specialist review, request the existing imaging reports and image files from the treating hospital. Confirm how those records can be transferred to the reviewing team rather than assuming that hospitals already share them automatically.

Sources: [2]

Sources and data notes

  1. FDA: expanded Anktiva indication

    Approval announced October 14, 2026. Original checked October 15. Record-preparation points are our editorial interpretation, not a patient-specific treatment recommendation.

  2. China NHSA: October 13 meeting and policy priorities

    Published October 14, 2026 about the October 13 meeting. Original Chinese report checked October 15. No separate effective date or overseas-patient entitlement stated.

Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.

All healthcare updates